Cyclo Therapeutics Inc
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials fo… Read more
Cyclo Therapeutics Inc (CYTH) - Total Assets
Latest total assets as of September 2024: $5.25 Million USD
Based on the latest financial reports, Cyclo Therapeutics Inc (CYTH) holds total assets worth $5.25 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cyclo Therapeutics Inc - Total Assets Trend (2000–2024)
This chart illustrates how Cyclo Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cyclo Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Cyclo Therapeutics Inc's total assets of $5.25 Million consist of 93.0% current assets and 7.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 69.8% |
| Accounts Receivable | $122.38K | 0.9% |
| Inventory | $254.35K | 1.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Cyclo Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cyclo Therapeutics Inc's current assets represent 93.0% of total assets in 2024, an increase from 17.8% in 2000.
- Cash Position: Cash and equivalents constituted 69.8% of total assets in 2024, up from 3.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 1.9% of total assets.
Cyclo Therapeutics Inc Competitors by Total Assets
Key competitors of Cyclo Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Cyclo Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cyclo Therapeutics Inc generates 0.08x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cyclo Therapeutics Inc is currently not profitable relative to its asset base.
Cyclo Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.17 | 0.83 | 1.26 |
| Quick Ratio | 0.16 | 0.80 | 1.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-15.46 Million | $ -1.11 Million | $ 816.95K |
Cyclo Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Cyclo Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 59.10 |
| Latest Market Cap to Assets Ratio | 0.63 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $13.25 Million |
| Market Capitalization | $8.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cyclo Therapeutics Inc's assets below their book value (0.63 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Cyclo Therapeutics Inc's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Cyclo Therapeutics Inc (2000–2024)
The table below shows the annual total assets of Cyclo Therapeutics Inc from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $13.25 Million | 0.00% |
| 2023-12-31 | $13.25 Million | +214.28% |
| 2022-12-31 | $4.22 Million | -78.41% |
| 2021-12-31 | $19.52 Million | +37.59% |
| 2020-12-31 | $14.19 Million | +244.94% |
| 2019-12-31 | $4.11 Million | +40.97% |
| 2018-12-31 | $2.92 Million | +39.70% |
| 2017-12-31 | $2.09 Million | +11.78% |
| 2016-12-31 | $1.87 Million | -60.72% |
| 2015-12-31 | $4.76 Million | -9.99% |
| 2014-12-31 | $5.29 Million | +89.47% |
| 2013-12-31 | $2.79 Million | +6.54% |
| 2012-12-31 | $2.62 Million | -6.17% |
| 2011-12-31 | $2.79 Million | +44.45% |
| 2010-12-31 | $1.93 Million | +49.11% |
| 2009-12-31 | $1.30 Million | +5.21% |
| 2008-12-31 | $1.23 Million | -22.98% |
| 2007-12-31 | $1.60 Million | +110.23% |
| 2006-12-31 | $760.46K | -0.50% |
| 2005-12-31 | $764.28K | -24.32% |
| 2004-12-31 | $1.01 Million | +17.03% |
| 2003-12-31 | $862.97K | +76.20% |
| 2002-12-31 | $489.77K | +4.60% |
| 2001-12-31 | $468.21K | -15.15% |
| 2000-12-31 | $551.78K | -- |